Interleukin-Targeting Bispecific Antibody: PK, ADA, and Pharmacodynamic Immunoassay Development and Validation for Clinical Trials

The therapeutic was designed to simultaneously engage two cytokine targets, and this dual binding architecture created a compounding set of bioanalytical challenges that could not be addressed using standard single target assay approaches. Each assay type required an independent development strategy tailored to the structural and pharmacological properties of the bispecific molecule.

For PK assay development, the primary requirement was engineering sufficient sensitivity to accurately capture drug concentrations across both low dose and high dose cohorts within a single analytical run. The inherently wide dose range of the clinical program demanded a long dynamic quantitation range without sacrificing lower limit of quantitation (LLOQ) performance. In addition, the assay exhibited matrix intolerance at standard dilution factors, a common obstacle with complex biological matrices, necessitating careful buffer optimization to preserve assay integrity while meeting regulatory sensitivity requirements. Achieving the target sensitivity in the low dose groups while maintaining quantitative accuracy in high dose samples within a single validated method represented a fundamental design constraint.

The ADA assay presented a distinct and clinically significant challenge: developing an ADA assay drug tolerant to circulating drug concentrations up to 300 µg/mL. High drug levels at the time of sampling are common in clinical trials, particularly during and shortly after dosing, and can mask or suppress ADA signals in standard bridging assay immunogenicity formats. Achieving adequate drug tolerance without compromising sensitivity to low titer ADA, which may be clinically meaningful even at low levels, required a fundamentally modified sample preparation strategy that went beyond conventional acid dissociation approaches.

For the pharmacodynamic assay target engagement measurements, the sponsor required dual target engagement assessments for both interleukin targets of the bispecific molecule. Developing a drug bound cytokine assay capable of quantifying target engagement in the presence of circulating bispecific antibody proved especially complex, as steric hindrance from excess free drug and heterophilic interactions between assay components impaired signal detection. Conventional antibody capture strategies failed to achieve adequate sensitivity and specificity without extensive optimization, and both the capture antibody selection and assay diluent formulation required iterative redesign to overcome these matrix driven interferences.